Back to your search result

Description

Selectively inhibits the mammalian target of rapamycin (mTOR) and blocks the subsequent activation of p70 S6 kinase (IC50 = 50 pM). Specifically inhibits mTORC1, but mTORC2 that phosphorylates Akt at Ser473 appears to be insensitive to rapamycin. Prevents the translational activation of IGF-II. Also prevents resting T-cells from entering the cell cycle, but does not directly arrest cell cycle progression. Shown to inhibit later signaling events, such as p110Rb phosphorylation, p34cdc2 kinase activation, and cyclin A synthesis. Exhibits strong binding to FK-506 binding proteins. Also reported to induce apoptosis in a murine B-cell line, to inhibit lymphokine-induced cell proliferation at the G1 phase, and to irreversibly arrest Saccharomyces cerevisiae cells in the G1 phase., Anti-fungal and immunosuppressant. Selectively inhibits the mammalian target of rapamycin (mTOR) and blocks the subsequent activation of p70 S6 kinase (IC50 = 50 pM). Specifically inhibits mTORC1, but mTORC2 that phosphorylates Akt at Ser473 appears to be insensitive to rapamycin. Prevents the translational activation of IGF-II. Also prevents resting T-cells from entering the cell cycle, but does not directly arrest cell cycle progression. Shown to inhibit later signaling events, such as p110Rb phosphorylation, p34cdc2 kinase activation, and cyclin A synthesis. Exhibits strong binding to FK-506 binding proteins. Also reported to induce apoptosis in a murine B-cell line, to inhibit lymphokine-induced cell proliferation at the G1 phase, and to irreversibly arrest Saccharomyces cerevisiae cells in the G1 phase. A 5 mM (500 µ,g/109 µ,l) solution of Rapamycin (Cat. No. 553211) in DMSO and a 10 mM (1 mg/109 µ,l) solution of Rapamycin (Cat. No. 553212) in EtOH is also available.